Snyder Biomedical Corporation focuses on innovative therapies aimed at treating and preventing age-related macular degeneration (AMD), a leading cause of blindness in developed countries. The company has developed a novel approach utilizing L-DOPA, a compound that interacts with the GPR143 receptor on retinal pigment epithelial (RPE) cells. Research led by Dr. Brian McKay demonstrated that L-DOPA can reduce the secretion of vascular endothelial growth factor (VEGF), which is responsible for the abnormal blood vessel growth associated with neovascular AMD. Clinical trials have shown promising results, with patients experiencing decreased fluid leakage and improved vision, suggesting that L-DOPA could serve as an effective adjunct therapy to traditional anti-VEGF injections.

In addition to its ongoing research, Snyder Biomedical has secured patents for its therapeutic methods and is actively pursuing partnerships to further develop its findings. The company aims to reduce the frequency of injections required for AMD treatment, potentially saving significant healthcare costs. With projections indicating a doubling of AMD cases in the coming decades, Snyder Biomedical's work is positioned to make a substantial impact on both patient outcomes and the economic burden of vision impairment associated with this condition.

United States

Snyder Biomedical Corporation was incorporated in 2008 by Robert W. Snyder, MD, PhD, an ophthalmologist and cell biologist, and John A. Martens.

Snyder Biomedical

Company Details